<DOC>
	<DOCNO>NCT01501656</DOCNO>
	<brief_summary>Promoter region hypermethylation tumor suppressor gene one early molecular event malignant transformation readily detectable apparently normal benign breast epithelium adjacent breast cancer . The investigator hypothesize DNA methylation certain gene occurs field change benign breast tissue high risk malignant transformation , , exploit tissue-based breast cancer risk stratification . Additional work require identify new DNA methylation marker potentially useful periareolar fine needle aspiration ( RP-FNA ) -based breast cancer risk stratification , determine whether marker methylated frequently benign sample woman develop breast cancer , determine whether assessment marker reproducible , determine whether tamoxifen reduces DNA methylation , good understand pattern DNA methylation benign sample unselected healthy control population . Each objective contribute advancement clinically useful RP-FNA-based breast cancer risk stratification test . In addition , identification gene preferentially methylated estrogen receptor ( ER ) negative breast cancer provide clue underlie biology responsible aggressive form breast cancer . This knowledge may lead discovery cause ER negative breast cancer , approach recognize woman increase risk type breast cancer , approach reduce risk . This study seek identify pattern DNA methylation benign breast epithelial cell associate increase risk breast cancer focus ER negative breast cancer .</brief_summary>
	<brief_title>Epigenetic Testing Breast Cancer Risk Stratification</brief_title>
	<detailed_description>Promoter region hypermethylation tumor suppressor gene one early molecular event malignant transformation readily detectable apparently normal benign breast epithelium adjacent breast cancer . We hypothesize DNA methylation certain gene occurs field change benign breast tissue high risk malignant transformation , , exploit tissue-based breast cancer risk stratification . Additional work require identify new DNA methylation marker potentially useful periareolar fine needle aspiration ( RP-FNA ) -based breast cancer risk stratification , determine whether marker methylated frequently benign sample woman develop breast cancer , determine whether assessment marker reproducible , determine whether tamoxifen reduces DNA methylation , good understand pattern DNA methylation benign sample unselected healthy control population . Each objective contribute advancement clinically useful RP-FNA-based breast cancer risk stratification test . In addition , identification gene preferentially methylated estrogen receptor ( ER ) negative breast cancer provide clue underlie biology responsible aggressive form breast cancer . This knowledge may lead discovery cause ER negative breast cancer , approach recognize woman increase risk type breast cancer , approach reduce risk .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Women age 30 79 . Untreated stage 1 3 invasive breast cancer woman never diagnose breast cancer . BIRADS 1 , 2 , 3 breast imaging within 12 month woman &gt; 40 year age recruit control group . &lt; 30 &gt; 80 year age Unable provide inform consent Presence undefined palpable mammographic breast lesion suspicious malignancy ( BIRADS 4 5 ) Breast implant Bilateral prophylactic mastectomy Any prior breast irradiation Any systemic chemotherapy past Performance status restrict normal activity significant portion day Use luteinizinghormonereleasinghormone ( LHRH ) analog , prolactin inhibitor , antiandrogens , systemic glucocorticoid within three month Ever use tamoxifen , raloxifene , SERMs Ever use aromatase inhibitor Pregnancy lactation within six month Bleeding diathesis kind 1 . Inherited coagulation disorder 2 . Current coumadin use 3 . Use drug inhibit platelet aggregation within 10 day</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>